Wolverine Trading
LCTX icon

Wolverine Trading’s Lineage Cell Therapeutics LCTX Stock Holding History

Wolverine Trading’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,900
Closed -$30K – 5980
2021
Q4 		$30K Buy
11,900
+1,800
+18% +$4.21K ﹤0.01% 5450
2021
Q3 		$26K Sell
10,100
-14,600
-59% -$37.5K ﹤0.01% 6115
2021
Q2 		$72K Buy
24,700
+4,800
+24% +$12.4K ﹤0.01% 5521
2021
Q1 		$45K Sell
19,900
-21,100
-51% -$50.7K ﹤0.01% 5669
2020
Q4 		$71K Buy
+41,000
New +$57.3K ﹤0.01% 4552
2019
Q3 		– Sell
-20,100
Closed -$22K – 4720
2019
Q2 		$22K Sell
20,100
-4,000
-17% -$4.61K ﹤0.01% 4282
2019
Q1 		$32K Buy
+24,100
New +$30K ﹤0.01% 4370
2018
Q4 		– Sell
-31,775
Closed -$65K – 4946
2018
Q3 		$65K Sell
31,775
-3,429
-10% -$7.2K ﹤0.01% 4651
2018
Q2 		$83K Hold
35,204
– – ﹤0.01% 4786
2018
Q1 		$83K Buy
+35,204
New +$82.6K ﹤0.01% 4786
2017
Q4 		– Sell
-11,773
Closed -$29K – 5224
2017
Q3 		$29K Sell
11,773
-7,772
-40% -$19.3K ﹤0.01% 4289
2017
Q2 		$54K Buy
+19,545
New +$54.6K ﹤0.01% 4039
2017
Q1 		– Sell
-19,888
Closed -$63K – 4681
2016
Q4 		$63K Buy
+19,888
New +$61.1K ﹤0.01% 4174

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wolverine Trading's LCTX Position: Q3 2021 in Review

Wolverine Trading sold out of Lineage Cell Therapeutics (LCTX) in Q3 2021, closing a stake of 13,482 shares — an estimated $34.6K sold.

Wolverine Trading first reported a position in LCTX in Q2 2016 and held it in 11 quarters. The position peaked at $61K in Q4 2017. 115 funds tracked by Wall St. Rank hold LCTX as of Q3 2021.

  • Wolverine Trading reported no remaining Lineage Cell Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Wolverine Trading sold 13,482 Lineage Cell Therapeutics shares in Q3 2021, an estimated $34.6K.
  • Wolverine Trading first reported a position in Lineage Cell Therapeutics in Q2 2016 and held it in 11 quarters.
  • Wolverine Trading's Lineage Cell Therapeutics position peaked at $61K in Q4 2017.
  • 115 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2021.

Based on Wolverine Trading's 13F filing for Q3 2021, filed 12 Nov 2021.